Literature DB >> 29521183

Short- and long-term mortality after pulmonary embolism in patients with and without cancer.

Ghazi Alotaibi1,2, Cynthia Wu1, Ambikaipakan Senthilselvan3, Michael Sean McMurtry1.   

Abstract

Pulmonary embolism (PE) is a major cause of mortality and morbidity. It is known that the risk of death varies by provoking factors; however, it is unknown if the risk of death persists beyond the initial diagnosis among patients with cancer-associated and non-cancer provoked patients. In this study, we aimed to investigate the effect of cancer on overall, short- and long-term mortality in a cohort of consecutive incident PE patients. Using administrative databases, we identified all incident cases of PE between 2004 and 2012 in Alberta, Canada. Cases were stratified by provoking factors (i.e. unprovoked, provoked, and cancer-associated). A multivariate Cox survival model was used to estimate the hazard ratios of short- and long-term death. We identified 8641 patients with PE, among which 42.2% were unprovoked, 37.9% were provoked and 19.9% were cancer-associated. The 1-year and 5-year survival probabilities were 60% (95% CI: 57-64%) and 39% (95% CI: 36-43%) in patients with cancer-associated PE, 93% (95% CI: 92-94%) and 80% (95% CI: 78-81%) in provoked PE, and 94% (95% CI: 93-95%) and 85% (95% CI: 83-87%) in unprovoked PE, respectively. Compared to patients with unprovoked events, both short-term and long-term survival in patients with cancer-associated PE have a higher observed risk of all-cause mortality in all age groups ( p<0.001). In contrast, patients with provoked events had a similar short- and long-term all-cause mortality. While PE has a significant mortality in all risk groups, patients with cancer have a higher risk of short-term mortality compared to patients with unprovoked PE.

Entities:  

Keywords:  AB-VTE; cancer; mortality; pulmonary embolism (PE); venous thromboembolism (VTE)

Mesh:

Substances:

Year:  2018        PMID: 29521183     DOI: 10.1177/1358863X18754692

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  7 in total

1.  Blood Urea Nitrogen to Serum Albumin Ratio Independently Predicts Mortality in Critically Ill Patients With Acute Pulmonary Embolism.

Authors:  Jihong Fang; Bin Xu
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

2.  In-hospital and short-term predictors of mortality in patients with intermediate-high risk pulmonary embolism.

Authors:  Gulay Gök; Mehmet Karadağ; Tufan Çinar; Zekeriya Nurkalem; Dursun Duman
Journal:  J Cardiovasc Thorac Res       Date:  2020-11-28

3.  Concurrence of Gastric Cancer and Incidental Pulmonary Embolism May Be a Prognostic Factor for Advanced Gastric Cancer Patients with Incidental Pulmonary Embolism.

Authors:  Meiqing Qiu; Ying Meng; Huijun Wang; Li Sun; Zhen Liu; Shifeng Kan; Tao Wang; Shu Zhang
Journal:  Cancer Manag Res       Date:  2021-10-04       Impact factor: 3.989

4.  Efficacy of Rivaroxaban Use in Solid Tumour Malignancy: Experience from a Tertiary Care Cancer Centre.

Authors:  Azmi Nor Mohd Farez Ahmat; Sharifa Ezat Wan Puteh; Suhana Yusak
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

Review 5.  Cardiogenic shock among cancer patients.

Authors:  Anais Curtiaud; Clement Delmas; Justine Gantzer; Lara Zafrani; Martin Siegemund; Ferhat Meziani; Hamid Merdji
Journal:  Front Cardiovasc Med       Date:  2022-08-22

Review 6.  Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.

Authors:  Géraldine Poenou; Teona Dumitru Dumitru; Ludovic Lafaie; Valentine Mismetti; Elie Ayoub; Cécile Duvillard; Sandrine Accassat; Patrick Mismetti; Marco Heestermans; Laurent Bertoletti
Journal:  J Clin Med       Date:  2022-09-25       Impact factor: 4.964

7.  Performance of pulmonary embolism severity index in predicting long-term mortality after acute pulmonary embolism.

Authors:  Abdulsamet Sandal; Elif Tuğçe Korkmaz; Funda Aksu; Deniz Köksal; Ziya Toros Selçuk; Ahmet Uğur Demir; Salih Emri; Lütfi Çöplü
Journal:  Anatol J Cardiol       Date:  2021-08       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.